Antibody Response against SARS-CoV-2 after mRNA Vaccine in a Cohort of Hospital Healthy Workers Followed for 17 Months
Domenico Tripodi, Roberto Dominici, Davide Sacco, Claudia Pozzobon, Simona Spiti, Rosanna Falbo, Paolo Brambilla, Paolo Mascagni, Valerio Leoni

TL;DR
This study tracks antibody levels in hospital workers over 17 months to understand how mRNA vaccines protect against SARS-CoV-2 and how immunity changes over time.
Contribution
The study provides longitudinal data on antibody response in vaccinated hospital workers and identifies a critical antibody threshold for protection against SARS-CoV-2.
Findings
Antibody levels declined over time but remained higher in emergency and medical departments.
An antibody concentration of 550 BAU/mL was identified as a threshold for susceptibility to infection.
No differences in infection risk after the third vaccine dose were found across hospital departments.
Abstract
The assessment of antibody response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is of critical importance to verify the protective efficacy of available vaccines. Hospital healthcare workers play an essential role in the care and treatment of patients and were particularly at risk of contracting the SARS-CoV-2 infection during the pandemic. The vaccination protocol introduced in our hospital protected the workers and contributed to the containment of the infection’ s spread and transmission, although a reduction in vaccine efficacy against symptomatic and breakthrough infections in vaccinated individuals was observed over time. Here, we present the results of a longitudinal and prospective analysis of the anti-SARS-CoV-2 antibodies at multiple time points over a 17-month period to determine how circulating antibody levels change over time following natural infection…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsSARS-CoV-2 and COVID-19 Research · COVID-19 Clinical Research Studies · COVID-19 epidemiological studies
